Literature DB >> 8827879

[Chemotherapy for two patients with non-Hodgkin's lymphoma in hemodialysis].

F Sano1, M Koike, M Ishibashi, K Tuji, M Katoh, S Hasegawa, T Maeba, M Takahashi, S Ohwada, T Inoue, M Ishida.   

Abstract

There are few reports on chemotherapy of non-Hodgkin's lymphoma (NHL) in patients with chronic renal failure. Two long-term hemodialysis patients were treated for NHL with modified CHOP therapy. The plasma pharmacokinetics of adriamycin (ADR) and etoposide (VP-16) were investigated in these patients. In the first case, NHL was diagnosed in a 37-year-old male (diffuse pleomorphic, T cell type, stage I E). After 4 courses of chemotherapy, he achieved complete remission. The second case, was a 56-year-old male who was admitted to our hospital with melena and abdominal pain. A diagnosis of NHL (diffuse mixed, B cell type, stage III E) was made. Complete remission was achieved with 2 courses of chemotherapy. Levels of hematological and neurological toxicity were moderately severe but tolerable. Pharmacokinetics of ADR and VP-16 in these patients were similar to those in patients with normal renal function. These results suggested that ADR and VP-16 were effective drugs for hemodialysis patients with NHL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827879

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  Pyrexia of unknown origin (PUO) in a hemodialysis patient.

Authors:  Ananthakrishnapuram N Aravindan; John Saunders; Bruce Cleland; Tim Spicer; Ken Howlin; Jeff Wong; Andrew Jefferys; Josephine Chow; Christopher Henderson; Michael Suranyi
Journal:  Int Urol Nephrol       Date:  2007-09-26       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.